In a phase 2, double-blind, randomized, placebo-controlled trial,patients with stage 3 T1D (n = 91) that received baricitinib (4) mg once per day) orally for 48 weeks had higher C-peptide,lower insulin requirement, similar HbA1c and lower glucose variation than those inplacebo group. This evidence concerns the gene INS and type 1 diabetes mellitus.